Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?

Publication Date

2015

Journal Title

Curr Treat Options Cardiovasc Med

Abstract

OPINION STATEMENT: The development of bare metal stent (BMS) was a major advancement over plain old balloon angioplasty (POBA) in the management of symptomatic coronary artery disease. BMS prevented restenosis by attenuating early arterial recoil and contraction; both seen commonly after POBA. However, the rate of clinically indicated target lesion repeat revascularization due to a process of in-stent restenosis (ISR) at 1 year remained relatively high (10 to 20 %), often due to excessive neointimal growth (Fischman et al. N Engl J Med. 331:496, 1994; Serruys et al. N Engl J Med. 331:489, 1994; Cutlip et al. J Am Coll Cardiol 40:2082, 2002). Stents with drug elution technology (DES) were developed to reduce the relatively high rate of ISR and subsequent repeat revascularization seen with BMS. Clinical trials have confirmed a reduction of as much as 50 to 70 % in target lesion revascularization by DES compared to BMS. These findings have led to the preferential use of DES in the majority of percutaneous coronary intervention (PCI). However, as DES require a longer period of dual antiplatelet therapy (DAPT) to prevent stent thrombosis, DES are not appropriate for all patients.

Volume Number

17

Issue Number

8

Pages

393

Document Type

Article

EPub Date

2015/07/15

Status

Faculty

Facility

School of Medicine

Primary Department

Cardiology

PMID

26154294

DOI

10.1007/s11936-015-0393-y

For the public and Northwell Health campuses

Share

COinS